NM5072

About NovelMed Therapeutics

NovelMed Therapeutics is a privately held, pre-revenue biotech founded in 2012, focused on developing first-in-class and best-in-class antibody therapies that selectively inhibit the complement Alternative Pathway. Its lead asset, Ruxoprubart (NM8074), has generated promising Phase II proof-of-concept data in PNH and holds Orphan Drug Designation, positioning it to address a significant share of the rare disease market. The company's highly differentiated mechanism aims for a favorable safety profile and supports a broad pipeline targeting over 20 indications across ophthalmology, nephrology, hematology, and neurology. NovelMed is actively seeking partnerships and investment to advance its clinical programs and capitalize on an addressable market estimated at over $400 billion.

Therapeutic Areas